Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00899678




Registration number
NCT00899678
Ethics application status
Date submitted
29/04/2009
Date registered
12/05/2009
Date last updated
7/08/2018

Titles & IDs
Public title
The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents
Scientific title
A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)
Secondary ID [1] 0 0
2014-004381-24
Secondary ID [2] 0 0
C87035
Universal Trial Number (UTN)
Trial acronym
NURTURE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Certolizumab Pegol
Treatment: Drugs - Certolizumab Pegol

Active comparator: Maintenance High-Dose - Maintenance High-Dose group: 400 mg Certolizumab Pegol for subjects = 40 kg or 200 mg Certolizumab Pegol for subjects 20 to \< 40 kg

Active comparator: Maintenance Low-Dose - Maintenance Low-Dose group: 200 mg Certolizumab Pegol for subjects = 40 kg or 100 mg Certolizumab Pegol for subjects 20 to \< 40 kg


Treatment: Drugs: Certolizumab Pegol
400 mg administered subcutaneously at once every 4 weeks for subjects = 40 kg or 200 mg for subjects 20 to \< 40 kg

\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects = 40 kg or 200 mg for subjects 20 to \< 40 kg

Treatment: Drugs: Certolizumab Pegol
200 mg administered subcutaneously at once every 4 weeks for subjects = 40 kg or 200 mg for subjects 20 to \< 40 kg

\*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects = 40 kg or 200 mg for subjects 20 to \< 40 kg
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Subjects in Clinical Remission at Week 62
Timepoint [1] 0 0
Week 62
Secondary outcome [1] 0 0
Absolute Pediatric Crohn's Disease Activity Index (PCDAI) Scores at Week 62
Timepoint [1] 0 0
Week 62
Secondary outcome [2] 0 0
Change in Pediatric Crohn's Disease Activity Index (PCDAI) Scores From Week 0 to the End of the Study (Week 62)
Timepoint [2] 0 0
From Week 0 to Week 62
Secondary outcome [3] 0 0
Percentage of Subjects Achieving Clinical Response From Week 0 to the End of the Study (Week 62)
Timepoint [3] 0 0
From Week 0 to Week 62
Secondary outcome [4] 0 0
C-Reactive Protein (CRP) Levels at Week 62
Timepoint [4] 0 0
Week 62
Secondary outcome [5] 0 0
Change in C-Reactive Protein (CRP) Levels From Week 0 to the End of the Study (Week 62)
Timepoint [5] 0 0
From Week 0 to Week 62
Secondary outcome [6] 0 0
Erythrocyte Sedimentation Rate (ESR) at Week 62
Timepoint [6] 0 0
Week 62
Secondary outcome [7] 0 0
Change in Erythrocyte Sedimentation Rate (ESR) From Week 0 to the End of the Study (Week 62)
Timepoint [7] 0 0
From Week 0 to Week 62
Secondary outcome [8] 0 0
Change in Growth Scores (Tanner Stage [Assessing Puberty]) From Week 0 to the End of the Study (Week 62)
Timepoint [8] 0 0
From Week 0 to Week 62
Secondary outcome [9] 0 0
Percentage of Subjects Who Initiated Steroid Tapering
Timepoint [9] 0 0
From Week 2 up to Week 8
Secondary outcome [10] 0 0
Percentage of Subjects in Corticosteroid-free Remission at the End of the Study
Timepoint [10] 0 0
Last/Withdrawal Visit (up to Week 62)

Eligibility
Key inclusion criteria
* Subjects with active Crohn's Disease (CD) confirmed 3 months prior to Screening
* Subjects with a Pediatric Crohn's Disease Activity Index (PCDAI) score of > 30 at Week 0
* Subjects between the ages of 6 and 17, inclusive, prior to baseline dosing
* Subjects must weigh > 20 kg (44 lbs)
* Subjects must have normal Electrocardiogram (ECG) or no medically relevant abnormalities as assessed by the investigator
* Subjects must meet Tuberculosis (TB) screening criteria
* Subjects taking corticosteroids, antibiotics and analgesics must have stable dosing, as defined, for one week
Minimum age
6 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects who score > 5 on the perirectal disease item of the PCDAI at Baseline
* Subjects who have had an active enterocutaneous fistulae within 3 months prior to Baseline
* Subjects with non-enterocutaneous fistulae, signs or symptoms of bowel obstruction or short bowel syndrome
* Subjects with a functional colostomy or ileostomy
* Subjects who have had surgical bowel resection within 6 months prior to Baseline or who may be planning any resection while enrolled in the study
* Subjects with clinical suspicion of intraabdominal abscesses
* Subjects with a positive stool result for enteric pathogens and/or parasites
* Subject has received any investigational biological therapies (within or outside a clinical trial) within 12 weeks prior to Screening or has been dosed in any clinical trial using non biological therapies within 4 weeks prior to Screening
* Subjects who have lost response to another Tumor Necrosis Factor (TNF) agent
* Subjects may not use another TNF agent within 12 weeks of Screening Visit
* Subjects with any prior exposure to natalizumab
* Subjects who have received mycophenolate or thalidomide within 4 weeks prior to Screening
* Subjects who have received cyclosporin or tacrolimus within 6 months prior to Screening
* Subjects who have received parenteral corticosteroids within 2 weeks prior to Screening
* Subjects who have received corticosteroids or corticotrophins for indications other than CD within 2 weeks of Screening
* Subject has a current or recent history (within 6 months prior to Screening) of significant and severe renal, hepatic, hematological, gastrointestinal (other than CD), endocrine, pulmonary, cardiac, neurological, or cerebral disease including blood dyscrasia (eg, pancytopenia, aplastic anemia), demyelinating disease (eg, multiple sclerosis, myelitis, optic neuritis), or ischemic heart disease
* Subjects with a current sign or symptom indicating recent or chronic infections (including herpes zoster)
* Subject has negative test for Immunoglobulin G (IgG) against Varicella zoster (chicken pox)
* Subjects who have not completed their primary vaccination series, or are planning to have a live vaccine administered during the study period or up to 3 months after last dose of study drug
* Subject has a history of TB or a positive chest x-ray suggestive of TB
* Subjects with known concurrent viral hepatitis or Acquired Immune Deficiency Syndrome (AIDS) or known Human Immunodeficiency Virus (HIV) infection
* Subjects with concurrent malignancy or history of malignancy, excluding treated squamous cell carcinoma of the skin
* Subject has concurrent bowel dysplasia or a history of bowel dysplasia in the 5 years prior to Screening
* Subjects with a history lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoma at any time

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/07/2012
Sample size
Target
Accrual to date
Final
99
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
- Randwick
Recruitment hospital [2] 0 0
- Herston
Recruitment hospital [3] 0 0
- Parkville
Recruitment postcode(s) [1] 0 0
- Randwick
Recruitment postcode(s) [2] 0 0
- Herston
Recruitment postcode(s) [3] 0 0
- Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Tennessee
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
British Columbia
Country [24] 0 0
Canada
State/province [24] 0 0
Nova Scotia
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
New Zealand
State/province [26] 0 0
Auckland
Country [27] 0 0
New Zealand
State/province [27] 0 0
Canterbury

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
UCB Celltech
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
UCB Clinical Trial Call Center
Address 0 0
+1 877 822 9493 (UCB)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00899678